Eczema drug dupilumab may rewire itch signals in skin

NCT ID NCT04823130

Completed Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at how dupilumab, an injectable eczema drug, changes nerve fibers in the skin of 54 adults with moderate-to-severe atopic dermatitis and chronic itching. Researchers took skin biopsies to measure nerve density and branching before and after treatment. The goal was to understand the biological reasons behind the drug's itch-relieving effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dupilumab (injection)
What this could lead to: If successful, this could help explain how dupilumab reduces itching in eczema by affecting skin nerves, potentially guiding better treatments.
What could go wrong: This is a small, exploratory Phase 4 study focused on understanding mechanisms, not proving a cure. Results may not lead to new treatments directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATITIS ATOPIC

Contacts and locations

Locations

Investigational Site Number 2760001

Münster, 48149, Germany
Investigational Site Number 8400001

Miami, Florida, 33136, United States
Investigational Site Number 8400002

East Windsor, New Jersey, 08520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.